Characterization of antibodies to SARS‐CoV‐2 in lyophilized plasma prepared with amotosalen‐UVA pathogen reduction

Abstract

BackgroundSevere acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)‐infected patients exhibit disease ranging from asymptomatic to severe pneumonia, multi‐organ failure, and death. convalescent COVID plasma (CCP) from recovered patients with high levels of neutralizing antibodies has demonstrated therapeutic efficacy to reduce the morbidity of coronavirus disease 2019 (COVID‐19) in some studies. The development of assays to characterize the activity of CCP to neutralize SARS‐CoV‐2 infectivity offers the possibility to improve potential therapeutic efficacy. Lyophilization of CCP may increase the availability of this therapy. We hypothesized that SARS‐CoV‐2 antibody profiles of pooled lyophilized pathogen‐reduced CCP from COVID‐19‐recovered blood donors retains virus‐neutralizing efficacy as reported for frozen pathogen‐reduced CCP.MethodsPooled lyophilized pathogen‐reduced plasma was prepared from recovered COVID plasma donors. Antibodies to SARS‐CoV‐2 were characterized in each donor plasma prior to pathogen reduction and lyophilization and after lyophilization of individual CCP, and in the lyophilized CCP pool. Several complimentary assays were used to characterize antibody levels, neutralizing capacity, and the spectrum of antigen reactivity. The mean values for individual plasma samples and the value in the pool were compared.ResultsThe mean ratio for antibody binding to SARS‐CoV‐2 antigens before and after treatment was 0.95 ± 0.22 mean fluorescent intensity (MFI) units. Antibody activity to an array of influenza virus antigens demonstrated a mean activity ratio of 0.92 ± 0.12 MFI before and after treatment.ConclusionsThe antibody activity in pooled pathogen‐reduced lyophilized CCPs demonstrated minimal impact due to pathogen reduction treatment and lyophilization.